Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children Hand-out Mar 31, 2026 Mar 31, 2026 Updated 33 sec ago Facebook Twitter WhatsApp SMS Email Print Copy article link Save Logo of Abbisko Hand-out As featured on Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children SHANGHAI, March 31, 2026 Facebook Twitter WhatsApp SMS Email Print Copy article link Save Sections AutomotiveBridalBusiness And CareersCommunity CaresEducationEspanolFamily LivingFashion, Beauty & FitnessFood, Recipes & EntertainingGift IdeasGreen LivingHealth & WellnessHome DecoratingHome ImprovementHot TopicsHow ToKitchen, Bed & BathLawn & GardenMoney & FinancePetsPress ReleasesReal EstateSeasonalSenior LivingSportsTech Talk & InnovationTravel
Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children SHANGHAI, March 31, 2026
